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INTRODUCTION
This publication summarizes the latest updates to the 
2017 version of the Italian Guidelines for the management 
and the use of antiretroviral drugs (Antinori et al., New 
Microbiol 2017) with the chapter related to HIV treatment 
notably revised in comparison to previous version. 
The implementation of a new method for drafting the 
guidelines was made necessary following the publication 
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of the Law No 24 of 8 March 2017 (http://www.gazzettauf-
ficiale.it/eli/id/2017/03/17/17G00041/sg). The objective of 
this new regulation is the harmonization of the relation-
ship between doctors and patients, through the approv-
al of the new National System Guidelines. The law also 
suggests to align guidelines to internationally recognized 
standards; as a result, the new recommendations were 
released using the Population, Intervention, Comparison 
and Outcome (PICO) question format according to the 
Preferred Reporting Items for Systematic Reviews and 
Meta-analyses (PRISMA) guidelines (Moher et al., 200). 
The new format was used to implement updated recom-
mendations concerning the diagnostic tools for immuno-
logical and virological monitoring, when to start therapy, 
what to start, treatment optimization and therapeutic 
failure.
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SUMMARY
The Italian Society for Infectious and Tropical Diseases (SIMIT) in collaboration with the Technical 
Health Committee (Sections L and M) of the Italian Ministry of Health have supported the renewal of the 
recommendations for the Italian guidelines for the use of antiretroviral agents and the diagnostic-clini-
cal management of HIV-1 infected persons. This publication summarizes the latest updates to the 2017 
version of the Italian Guidelines for the management of HIV-1 infected patients and the use of antiret-
roviral drugs. New recommendations were released framing the clinical questions the use of antiretrovi-
rals according to the Patient Intervention Comparator Outcome (PICO) methodology and the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) system. Diagnostic tools for im-
munological and virological monitoring, when to start, what to start, optimization and therapeutic failure 
were updated in order to include the recommendation obtained with these newly developed methods. For 
a complete review of clinical and therapeutic relevant topics we refer the reader to the extended version 
of the Guidelines.
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This is a short version of the full text Italian Guidelines 
for the use of antiretroviral drugs and the diagnostic-clin-
ical management of people with HIV-1 infection. This 
version should not be considered completely exhaustive 
with respect to the full text version of the Guidelines. For 
a complete review of clinical and therapeutic relevant top-
ics such as continuum of care, management of comorbid-
ities, as well as populations (elderly, women, immigrants, 
children), conditions (drug and/or alcohol addiction, de-
tention), and situations (transplants) requiring special at-
tention we refer the reader to the extended version of the 
Guidelines. Similarly, while references cited herein refer 
only to the current update, a complete review of literature 
is available in the extended version of the Guidelines (HIV/
AIDS Italian Expert Panel 2017).
METHODOLOGY
Based on the PICO methodology, (Guyatt et al., 2011) and 
the GRADE system, the HIV Guidelines Working Group 
decided to adopt a shared and univocal framing of clinical 
questions, specifying, for each question, the patient pop-
ulation, the intervention of interest, the comparator, and 
the outcomes of interest. The topics were selected based 
on the analysis of the scientific literature and the compar-
ison with other Guidelines. Clinical needs and questions 
have been identified analysing the controversial areas, in 
which the identification of reference criteria and recom-
mendations, according to the principles of evidence-based 
medicine, are pivotal for the clinical decisions. The lit-
erature review was based on a search strategy for Eng-
lish-language articles in PubMed. Randomized controlled 
trials (RCTs), retrospective or prospective cohort studies 
with a control (concurrent or historical group) and the 
abstracts from the last two years International conferenc-
es were included. A modified frame from DHHS Panel on 
Antiretroviral Guidelines for Adults and Adolescents was 
used to assess the strength of the recommendations (Table 
1) (DHHS Panel on Antiretroviral Guidelines for Adults 
and Adolescents 2014). Ratings were discussed and ap-
proved by the entire Panel according the usual rules.
DIAGNOSTIC TOOLS FOR VIROLOGICAL  
AND IMMUNOLOGICAL MONITORING
Virology
The burden of plasma HIV-RNA (viremia or viral load) is 
a surrogate marker that allows to predict the risk of clin-
ical progression of the infection (prognostic marker) and 
evaluate the extent of the therapeutic response (Mellors et 
al., 1996). Recent studies have highlighted a new unit of 
measurement, defined as “HIV-RNA copies produced per 
year” (HIV viremia copy-years), which corresponds to the 
area under the curve of longitudinal viremia values, and 
represents the cumulative amount of virus circulating in 
the organism within the indicated time frame. 
The achievement of permanently undetectable viremia is 
the goal of ART.
Integrase genotypic resistance test
Given the widespread use of integrase inhibitors (INI) in 
clinical practice and the different genetic barrier of these 
drugs, the characterization of the integrase gene becomes 
particularly useful, not only at the time of failure, but 
also at the beginning of therapy with this class of drugs. 
In this regard, an increase in the prevalence of resistance 
to integrase inhibitors has been observed in recent years 
in patients treated with antiretroviral therapy (Lepik et al., 
2017). In addition, cases of transmission of strains resistant 
to these drugs begin to be reported (Menza et al., 2017; Hurt 
et al., 2011; Hernandez et al., 2017). Finally, the high preva-
lence of polymorphisms potentially associated with INI re-
sistance in newly diagnosed patients (Casadella et al., 2017) 
Table 1 - Rating scheme for degree of recommendation (a) 
and level of evidence (b).
a) Degree of recommendation
A Highly recommended
B Moderately recommended
C Optional
b) Level of evidence
Level I The data are obtained from at least one controlled, 
randomized study with sufficient power or from a 
meta-analysis of controlled studies.
Level II The data are collated from non-randomized studies 
or from cohort observational studies.
Level III Recommendation based on case reviews or 
agreement among experts.
Table 2 - Management of genotypic resistance test in treatment naïve patients.
VIROLOGY
Protease and reverse transcriptase
Q.1 Is there any advantage in performing a genotypic resistance test  
in all naive patients?
R.1 genotypic resistance tests (GRT) in HIV-infected 
patients naive is always recommended [AII]
Q.2 Is there any advantage to perform a genotypic resistance test  
in all patients with virological failure?
R.2 GRT in HIV infected patients with virological failure  
is always recommended [AII]
Integrase
Q.3 Is there any benefit in assessing INI resistance test in HIV-infected 
patients naïve to therapy?
R.3 INI resistance test is recommended in naïve patients 
[BIII]
Q.4 Is there any benefit in assessing INI resistance in HIV-infected 
patients who start first-line regimens or other regimens containing INI?
R.4 INI resistance test is recommended in all patients 
starting an INI-based regimen [AIII] 
Q.5 Is there any benefit in assessing INI resistance in HIV-infected 
patients who failed an INI regimen?
R.5 INI resR.5 INI resistance test is always recommended 
in all HIV-infected patients who failed INI based  
regimen [AI]
References for the table above: Lepik et al. 2017; Menza et al. 2011; Hernandez et al. 2017; Casadellà et al. 2015 Vandamme et al. 2011; Fernandez Caballero et al. 2016; 
Armenia et al. 2015; Katlama et al. 2016.
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indicates the usefulness of carrying out integrase resistance 
testing even in naïve patients in order to monitor the pos-
sible emergency of transmitted resistance to INI (Table 2).
Immunology
The CD4+ T cell counts are the only validated immuno-
logical diagnostic marker in randomized controlled trials. 
Despite several non-randomized and cohort studies tried 
to identify additional immunological markers (e.g CD4/
CD8 ratio), no other marker has been currently validated 
in the clinical management of HIV-1 infected patients. In 
subjects not treated with ART, CD4+T cell counts are re-
duced by about 4% per year. In response to therapy, a 50-
100 cells/μL/year increase in the number of CD4+T cells is 
obtained (Kaufmann et al., 2003). However, in a consid-
erable proportion of subjects (about 25%), called immu-
nological non-responders (INRs), this increase may be of 
a lower or variable extent (Gazzola et al., 2009). Indica-
tively, a count CD4+T cells lower than 200 cells/μL as well 
as a percentage of CD4+T cells below 14% are associated 
with an increased risk of opportunistic infections (Table 3) 
(Ledergerber et al., 2004; Gourlay et al., 2012).
CLINICAL GUIDELINES:  
ANTIRETROVIRAL THERAPY
When to start
The decision when to start ART has to take in account 
multiple factors that concern both the health of the 
HIV-infected patient, in the short and long term, and the 
role of ART in reducing the transmission of infection it-
self, also aiming at containing the epidemic (TasP, Treat-
ment as Prevention). It is for these reasons that is strongly 
recommended to provide ART to all people infected with 
HIV [AI]. It is specified that, to avoid the transmission of 
HCV to the partner, this panel recommends, nevertheless, 
the use of condoms in case of anal intercourse in subjects 
with active HIV/HCV co-infection [AIII] (Table 4) (Foster 
A. et al., 2016).
Opportunistic infections
In the course of opportunistic infection (OI), although the 
beginning of ART is always recommended, it is preferable 
to respect some deadlines (Table 5).
What to start?
First Line ART
The choice of a specific ART must be based on patients’ 
individual needs. 
The major advantage of the backbones comprising TDF, 
compared to the ones including ABC, lies in the fact that 
they do not require testing for the presence of HLA-B57 01 
and that they have a greater antiviral activity and genetic 
barrier against HBV. 
Furthermore, the initial (first 6 months) use of ABC has 
been correlated with increased risk of myocardial infarc-
tion in subjects with high cardio vascular risk (Sabin et al., 
2008; SMART/INSIGHT and the D:A:D Study Groups et 
Table 4 - When to start antiretroviral treatment.
WHEN TO START
Acute infection
Q.1 Is there any advantage in starting ART 
before the results of genotypic resistance 
tests for HIV and HLA-B5701 in HIV infected 
patients with an acute infection?
R.1 Immediate initiation of ART is recommended without waiting  
for the results [AII]. 
Chronic infection
Q.1 Is there any benefit in starting ART in HIV-
infected naïve patients with CD4 +>500 cells/μL 
compared to waiting to start when the CD4 + 
count is <500 cells/μL?
R.1 ART should be initiated in all subjects, regardless of the CD4+ cell count [AI] 
Rationale
The studies indicate that ART is associated with a clinical benefit on progression 
to AIDS or even death in subjects with CD4+ >500 cells/μL lymphocytes; early 
beginning of ART is also associated with an improved of quality of life.  
A further benefit of early ART initiation is a reduction in transmission of HIV.
References for the table above: Ananworanich et al. 2016; Henrich et al. 2017; INSIGHT START Study Group 2015; Temprano ANRS 12136 Study Group. 2015; O’Connor et 
al. 2017; Achhra et al. 2017; Kunisaki et al. 2016; Lifson et al. 2017.
Table 3 - Management of CD4+ in HIV-infected patients.
IMMUNOLOGY
Q.1 Is the monitoring of the absolute number  
of CD4+ T cells associated with the percentage 
value of CD4+ T cells and the CD4/CD8 ratio a 
better indicator of immunological recovery than 
the monitoring of the CD4+ T cells count alone?
R.1 The absolute number of CD4+ T cells is currently the most validated 
prognostic immunological marker, as it is the strongest predictor of clinical 
progression (AIDS and non-AIDS events). It allows to determine the indication 
at the beginning or the suspension of the prophylaxis for opportunistic 
infections. [AI].
Q.2 In which clinical context the association  
of the above mentioned markers can provide  
a real advantage?
R.2 The percentage value of CD4+ T cells and the CD4CD8 ratio should be 
evaluated in conjunction with the CD4+ T cell absolute count in order to obtain 
a better estimate of the immune system function, especially in patients with a 
risk of poor CD4+ T cell count recovery. (low CD4 + nadir, co-infections) [AII].
Q.3 It is believed that, in patients treated with  
ART and HIV-RNA <50 cp/µl and steady  
CD4+>500 cells/μl, monitoring frequency  
of CD4+T cell counts may be delayed and 
measured with intervals> 6 months [BII]
R.3 In ART treated patients with stable HIV-RNA <50 cp/µl and steady CD4 
+>500 cells/μl, monitoring frequency of CD4 + counts may be delayed and 
measured with intervals> 6 months [BII]
References for the table above: Duro et al. 2017; Caniglia et al. 2017; Gale et al. 2013; Hyle et al. 2013; Gianotti et al. 2017.
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al., 2008). On the other hand, ABC, compared to TDF, of-
fers the advantage of the possibility to be used in subjects 
with advanced renal insufficiency, without requiring dose 
adjustments (Table 6, 7, 8) (Sax et al., 2009; Sax et al., 2011; 
Daar et al., 2011; McComsey et al., 2011; Post et al., 2010; 
Moyle et al., 2013; Smith et al., 2009; Fabbiani et al., 2014; 
Walmsley et al., 2013; Orrell et al., 2017; Walmsley et al., 
2015; Wohl et al., 2016; Arribas et al., 2017; Gallant et al., 
2017; Bedimo et al., 2016; Costarelli et al., 2016; Winston 
et al., 2017).
Table 5 - When to start ART in a patient with an opportunistic infection.
Opportunistic Infections
Q.1 Is there any benefit to starting immediately ART in HIV-infected 
naïve patients with Pneumocystis jiroveci pneumonia compared  
to waiting to start at the end of pneumonia treatment? 
R.1 AIDS patients with Pneumocystis jiroveci must start 
ART within 2 weeks of diagnosis.
Q.2 Is there any benefit to starting immediately ART in HIV-infected 
naïve patients with pulmonary TB compared to waiting to start 15 days 
after starting TB therapy? 
R.2 In AIDS patients with pulmonary TB ART should be 
started within 2 weeks from the start of TB therapy when 
CD4+ is <50 cell/mmc, and within 8 weeks form start 
anti-TB therapy in all co-infected HIV/TB patients [AI]
Q.3 Is there any benefit to starting immediately ART in AIDS patients 
with TB meningitis compared to waiting the end of antibiotic treatment 
for TB?
R.3 In AIDS patient with TB meningitis ART should be 
started at the end of induction phase of TB treatment [AI]
Q.4 Is there any benefit to starting immediately ART in AIDS  
patients with cryptococcal meningitis compared to waiting the end  
of antibiotic treatment?
R.4 In AIDS patients with cryptococcal meningitis, ART 
should be started at the end of induction therapy [A1]
References for the table above: Torok et al. 2011; Makadzange et al. 2010; Boulware et al. 2014; Bicanic et al. 2009.
Table 6 - First line ART: the choice of backbones.
FIRST LINE ART
Recommended regimen options 
Q.1 What are the best two nucleoside reverse 
transcriptase inhibitors (NRTIs) to start therapy  
in terms of efficacy and tolerability in naïve  
HIV-infected patients?
R.1 In naïve HIV-infected patients, it is recommended to initiate therapy  
with regimens containing a tenofovir disoproxil fumarate (TDF)/emtricitabine 
(FTC) [AI] or tenofovir alafenamide (TAF)/FTC [AI] or, limited to the 
combination with dolutegravir, abacavir (ABC)/lamivudine (3TC) [AI].
Table 7 - First line ART: the choice of the third drug.
Options 
Q.1 What is the third favourite drug to start ART in terms  
of efficacy and tolerability in HIV-infected naïve patients?
R.1 A regimen based on integrase inhibitors (INSTI) [AI] is 
recommended for initiation of therapy in naïve patients, or, 
limited to patients with HIV-RNA <100,000 copies/mL and 
CD4+ >200 cells/μL, on RPV [AI]. Regimens based on boosted 
protease inhibitors are recommended only in conditions that 
do not favour adherence or starting treatment before the 
availability of the resistance test result is needed [AII] 
Q.2 Does ART with at least three antiretroviral principles active  
in a single tablet (3D-STR) offer advantages in terms of efficacy, 
quality of life and adherence compared to therapeutic regimens  
with the same 3 active drugs, but with multiple tablets (3D-MTR)  
as initial therapy in HIV-infected naïve patient?
R.2 In the initial therapy an antiretroviral regimen with at 
least three active ingredients in a single tablet (STR) has 
advantages in terms of adherence [BII] (AII for regimens  
with NNRTI) and efficacy [BIII] (AIII for NNRTI regimens) 
Q.3 Is the Dual Therapy (two different active antiretrovirals)  
an effective therapeutic option compared to ART with three active 
antiretroviral principles in HIV-infected naïve patients?
R.3 Dual therapy cannot be currently considered a 
therapeutic option similar to ART with three active drugs in 
terms of efficacy, and is therefore not recommended for the 
initiation of therapy in HIV-infected naïve patients [AI] 
Q.4 Does the addition of a fourth drug to an ART regimen composed 
of at least three active antiretroviral principles, offers advantages  
in terms of therapeutic efficacy in HIV-infected naïve patients  
with chronic infection and with HIV-RNA >500,000 cp/mL?
R.4 The addition of a fourth drug does not offer documented 
benefits over an ART regimen with three active ingredients 
and is therefore not recommended for initiation of therapy  
in the chronically infected patient [AI].
Q.5 Does the addition of a fourth drug to an ART regimen  
composed of at least three active antiretroviral principles  
offer advantages in terms of therapeutic efficacy in treatment  
of HIV-infected naïve patients with acute infection?
R.5 During acute infection the addition of a fourth drug does 
not offer documented benefits compared to an ART with 
three active drugs [AI] 
References to the above table: Orell et al. 2017; DeJesus et al. 2012; Eron et al., 2017; Molina et al. 2014; Cohen et al. 2014; Mills et al. 2015; Wohl et al. 2016; Astuti et al. 2014; 
Colombo et al. 2013; Engsig et al. 2014; Taneja et al. 2012; Fabbiani et al. 2016; Brunetta et al. 2015; Colombo et al. 2013; Homar et al. 2012; Rockstroh et al. 2013; Lennox 
et al. 2014; Cahn et al. 2017; Sax et al. 2012; DeJesus et al. 2012; Squires et al. 2016; Gallant et al. 2013; Gallant et al. 2015; Tashima et al. 2014; Mills et al. 2015; Eron et al. 
2017; Cohen et al. 2013; Molina 2011; Cohen 2012; Cohen 2014; Cohen 2011; Nelson 2013; Sax et al. 2015; Molina et al. 2015; Daar et al. 2011; Kulkarni 2017; Rhee et al. 
2015; Andreis et al. 2017; Slama et al. 2016; Dutertre et al. 2017; Stein et al. AIDS. 2015; Arkaiz et al. 2012; Crauwels et al. 2013; Raffi et al. 2014; Lambert-Niclot et al. 2016; 
Bernardino et al. 2015; Cahn et al. 2014; Stellbrink et al. 2016; Sued et al. 2017; Cahn et al. 2017; Taiwo et al. 2017; Crowell et al. 2016; Valcour, et al. 2015; Ostrowski et al. 
2015; Chéret et al. 2015; Markowitz et al. 2014.
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Treatment optimization
The main aims of therapeutic optimization are: overcom-
ing an ongoing toxicity (reactive switch); preventing pre-
dictable toxicity (preventive or proactive switch); promot-
ing adherence by safely reducing the number of tablets 
or doses; addressing unfavourable drug interactions. The 
therapeutic schemes listed in Table 9 represent the refer-
ence frame and every modification of the regimen must 
always consider the following priorities: maintaining vi-
rological suppression, and ensuring, with reasonable cer-
tainty, that the potential benefits for the patient outweigh 
the potential risks (the switch must ultimately be an ad-
vantage for the individual patient) (Table 9).
Therapeutic failure
The current availability of powerful and well tolerated 
antiretroviral drugs of various classes allows to set up 
long-lasting therapeutic regimens in the vast majority of 
patients. However, therapeutic failure due to the presence 
of a sub-optimal virological response (virological failure), 
unsatisfactory immunological response (immunological 
failure), as well as, to a lesser extent, clinical progression 
Table 8 - Antiretroviral regimens recommended for starting ART.
Regimen Degree of recommendation/
Level of evidence
Recommended regimen options (for all conditions)
TDF/FTC+RAL [AI]
TAF/FTC+RAL [AI]
TAF/FTC/EVG/COBI [AI]
TDF/FTC+DTG [AI]
TAF/FTC+DTG [AI]
ABC/3TC+DTG or ABC/3TC/DTG [AI]
TDF/FTC/RPV (for patients with HIV-RNA <100,000 copies/mL and T CD4+ count >200 cells/μl) [AI]
TAF/FTC/RPV
for patients with HIV-RNA <100.000 cp/mL and T CD4+ count >200 cells/μl)
[AII]
Recommended regimen options (for particular conditions)
TAF/FTC+ATV+r or TAF/FTC+DRV+r 
(Recommended in individuals with uncertain adherence or in patients who need to begin treatment 
before resistance testing results are available, or for therapy initiation in pregnant patients)
[AII]
TAF/FTC+ATV/COBI or TAF/FTC+DRV/COBI
(recommended in individuals with uncertain adherence or in patients who need to begin treatment 
before resistance testing results are available)
[AII]
References to the above table: Lennox et al. 2009; Raffi et al. 2013a; Raffi et al. 2013b; Rockstroh et al. 2013; Lennox et al. 2014; Sax et al. 2015; Clotet et al. 2014; Walmsley 
et al. 2013; Weller et al 2014; Molina et al. 2011; Cohen et al. 2012; Cohen et al. 2013a; Cohen et al. 2014; Ortiz et al. 2008; Molina et al. 2010; Daar et al. 2011; Soriano et al. 
2011; DeJesus et al. 2012; Gallant et al. 2013; Orkin et al. 2013; Clumeck et al. 2014; Lennox et al. 2014; Tashima et al. 2014; Gallant et al. 2015; Mills et al. 2015.
Table 9 - Antiretroviral regimens recommended for treatment optimization.
Treatment optimization
Q.1 In patients effectively treated with ART based on three 
active drugs in multiple tablets, does the switch to regimens 
that include ART with 3 drugs in a STR improve duration of 
the virological response, adherence and/or quality of life? 
R.1 Switching to a STR improves adherence in observational 
studies; no randomized trials addressed this issue; however, some 
STR improves quality of life and patients satisfaction [BII].
In terms of virological response the switch to STR proved to be not 
inferior to the standard regimen.
Q.2 In patients treated with ART based on three active 
drugs, does the switch to a dual therapy maintain virological 
response, reduce toxicity and improve tolerability? 
R.2 Virological suppression can be maintained with the switch  
to some regimens:
1. DTG+RPV [AI];
2. ATV/r+3TC, DRV/r+3TC [AI for switches from boosted PIs,  
BI for switches from other regimens];
3. DRV/r+RAL, DRV/r + RPV [CI];
4. DTG+3TC [BII].
Q.3: In patients treated with ART based on three active drugs, 
does the switch to monotherapy with a boosted PI or DTG 
maintain the virological suppression, reduce toxicity and 
improve tolerability?
R.3 The switch study from three active drugs to one single drug 
demonstrated insufficient control of HIV replication. DRV/r  
mono therapy [CI]. DTG mono therapy must to be avoided [AI].
Q.4 In patients treated with PI-based or NNRTI-based ART 
with three active drugs, does the switch to an INSTI or to 
a RPV-based regimen maintain virological suppression, 
reduce toxicity, improve tolerability and modify drug-drug 
interactions?
R.4 The following switches from a boosted PI are recommended: 
RPV [AI]; EVG/COBI/FTC/TDF [AI]; DTG [AI]. Also the switch from 
NNRTIs to an INSTI or RPV is recommended [AI]. I contrast, the 
switch from a boosted PI to MVC is optional [CI], and the switch 
from a boosted PI to RAL is recommended with caution [BI].
Q.5 In patients treated with three active drugs including 
TDF/FTC, does the switch to ABC/3TC- or from TDF to TAF 
maintain the virological suppression, reduce toxicity, improve 
tolerability and modify drug-drug interactions?
R.5 Switch from TDF/FTC based regimen to ABC/3TC - or TAF/FTC 
based regimen maintain virological suppression and reduces renal 
and bone toxicity [AI]. Caution is recommended for patients at risk 
for cardiovascular events [AI].
References to the above table: Airoldi et al. 2010; Raffi et al. 2015; Sterrantino et al. 2012; Molina et al. 2015; Walmsley et al. 2015; Palella et al. 2014; Arribas et al. 2017; 
Trottier et al. 2017.
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(clinical failure) still occur in a non-negligible proportion 
of patients (Table 10).
List of abbreviations
3TC: lamivudine; ABC: abacavir; ATV/r: ritonavir boosted 
atazanavir; ART: combined antiretroviral therapy; COBI: 
cobicistat; DTG: dolutegravir; DRV/r: ritonavir boost-
ed darunavir; EVG: elvitegravir; FDC: fixed dose combi-
nations; FTC: emitricitabine; NRTI: nucleoside reverse 
transcriptase inhibitor; NNRTI: Non-Nucleoside Reverse 
Transcriptase Inhibitor; RAL: raltegravir; RPV: rilpivirine; 
RTV: ritonavir; STR: single tablet regimens; TAF: tenofovir 
alafenamide; TDF: tenofovir disoproxil fumarate.
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Bologna; Breveglieri Michele, Arcigay, Verona; Bruno Raf-
faele, Policlinico San Matteo, Pavia; Calza Leonardo, Uni-
versità di Bologna; Capobianchi Maria Rosaria, Istituto 
Nazionale Malattie Infettive L. Spallanzani, Roma; Cagarelli 
Roberto, Regione Emilia-Romagna, Prevenzione Collettiva 
e Sanità Pubblica, Bologna; Calcagno Andrea, Università 
degli Studi di Torino; Castagna Antonella, Ospedale San 
Raffaele, Milano; Castelli Francesco, Università degli Studi 
di Brescia; Cattelan Anna Maria, Azienda Ospedaliera-Uni-
versitaria, Padova; Cauda Roberto, Università Cattolica del 
Sacro Cuore, Roma; Cingolani Antonella, Università Cattol-
ica del Sacro Cuore, Roma; Cinque Paola, Ospedale San Raf-
faele, Milano; Corbelli Giulio Maria, Plus Onlus, Bologna; 
d’Arminio Monforte Antonella, Università degli Studi di 
Milano; d’Ettorre Gabriella, Università degli Studi di Roma 
La Sapienza, Roma; De Carli Gabriella, Istituto Nazionale 
Malattie Infettive L. Spallanzani, Roma; De Luca Andrea, 
Azienda Ospedaliera Universitaria, Siena; Università Cattoli-
ca del Sacro Cuore, Roma; Di Biagio Antonio, Ospedale Poli-
clinico San Martino, Genova; Di Perri Giovanni, Università 
degli Studi di Torino; Di Pietro Massimo, Azienda Sanitaria 
di Firenze; El Hamad Issa, Azienda Ospedaliera Spedali Civi-
li, Brescia; Errico Margherita, NPS Italia Onlus, Milano; 
Gaeta Giovanni Battista, II Università di Napoli; Gargiulo 
Miriam, Azienda Ospedaliera D. Cotugno, Napoli; Gervaso-
ni Cristina, ASST Fatebenefratelli Sacco; Giacomet Vania, 
ASST Fatebenefratelli Sacco; Giannini Adriana, Regione 
Emilia-Romagna, Prevenzione Collettiva e Sanità Pubblica, 
Bologna; Gianotti Nicola, Ospedale San Raffaele, Milano; 
Giaquinto Carlo, Azienda Ospedaliera di Padova; Girardi 
Enrico, Istituto Nazionale Malattie Infettive L. Spallanza-
ni, Roma; Gori Andrea, Ospedale San Gerardo, Università 
di Milano-Bicocca, Monza; Grossi Paolo, Università degli 
Studi dell’Insubria, Varese; Guaraldi Giovanni, Università 
degli Studi di Modena e Reggio Emilia, Modena; Lichtner 
Miriam, Sapienza Università di Roma Polo Pontino, Roma; 
Liuzzi Giuseppina, Istituto Nazionale Malattie Infettive L. 
Spallanzani, Roma; Lo Caputo Sergio, Policlinico di Bari; 
Madeddu Giordano, Università degli Studi di Sassari; Mag-
gi Paolo, Policlinico di Bari; Maggiolo Franco, Ospedali Ri-
uniti di Bergamo; Marchetti Giulia, Università degli Studi 
di Milano; Marcotullio Simone, Nadir Onlus, Roma; Ma-
serati Renato, Policlinico San Matteo, Pavia; Mastroianni 
Claudio, Università degli Studi di Roma La Sapienza, Roma; 
Matteelli Alberto, Università degli Studi di Brescia; Men-
ichetti Francesco, Università degli Studi di Pisa; Mussini 
Cristina, Università degli Studi di Modena e Reggio Emilia, 
Modena; Nozza Silvia, Ospedale San Raffaele, Milano; Old-
rini Massimo, Lega Italiana per la Lotta contro l’AIDS, Mi-
lano; Parruti Giustino, Azienda Sanitaria Locale di Pescara; 
Pascucci Maria Grazia, Regione Emilia-Romagna, Prevenzi-
one Collettiva e Sanità Pubblica, Bologna; Parrella Roberto, 
Azienda Ospedaliera D. Cotugno, Napoli; Perno Carlo-Fed-
Table 10 - Management of antiretroviral failure.
Therapeutic failure
Q.1 Is the genotypic resistance tests (GRT) useful during 
ART in patients with low level viremia failure?
R.1 GRT is recommended in all patients before starting therapy and in 
all patients with virological failure [AI]. GRT in patients with low level 
viremia has proved to be reliable, also for the integrase enzyme [AII].
Q.2 Is the determination of the Therapeutic Drug 
Monitoring (TDM) for drugs used in patients in virological 
failure indicated in absence of resistance mutations?
R.2 The determination of the TDM for the drugs in use, even  
with the limitations inherent the execution and interpretation  
of the test, is a useful complement to the choice of the subsequent 
regimen and is therefore recommended [BII].
Q.3 Is the enhancement of ART with a fourth drug 
indicated in patients with frequent viral blip?
R.3 Intensification with a fourth drug in patients with frequent viral 
blip is not recommended [AII]
Q.4 Is simplification strategy advisable in patients  
with history of virological failure?
R.4 In these populations it is recommended a simplification  
with high genetic barrier drugs [BII]
References to the above table: Santoro et al. 2014; Armenia et al. 2015; Huhn et al. 2017.
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erico, Università degli Studi di Milano, ASST Grande Os-
pedale Metropolitano Niguarda, Milano; Pezzotti Patrizio, 
Istituto Superiore di Sanità, Roma; Prestileo Tullio, ARNAS 
Ospedale Civico-Benfratelli, Palermo; Puoti Massimo, Azien-
da Ospedaliera Ospedale Niguarda Ca’ Granda, Milano; Puro 
Vincenzo, Istituto Nazionale Malattie Infettive L. Spallanza-
ni, Roma; Rancilio Laura, Caritas Italiana, Milano; Ravizza 
Marina, Azienda Ospedaliera, Polo Universitario San Paolo, 
Milano; Rezza Gianni, Istituto Superiore di Sanità, Dipar-
timento di Malattie Infettive P.I., Roma; Ripamonti Diego, 
ASST Papa Giovanni XXIII, Bergamo; Rizzardini Giuliano, 
ASST Fatebenefratelli Sacco, Milano; Rusconi Stefano, Uni-
versità degli Studi di Milano; Santoro Maria, Università de-
gli Studi di Roma Tor Vergata, Roma; Sarmati Loredana, 
Università degli Studi di Roma Tor Vergata, Roma; Saracino 
Annalisa, Università degli Studi di Bari; Sighinolfi Laura, 
Azienda Ospedaliero, Universitaria di Ferrara; Stagnitta Ma-
ria, Coordinamento Nazionale delle Comunità di Accoglien-
za, Firenze; Starnini Giulio, Ospedale Belcolle di Viterbo, 
Viterbo; Sticchi Laura, Università degli Studi di Genova; 
Tamburrini Enrica, Università Cattolica del Sacro Cuore, 
Roma; Tambussi Giuseppe, Ospedale San Raffaele, Milano; 
Tavio Marcello, Azienda Ospedaliero-Universitaria Ospedali 
Riuniti di Ancona; Torti Carlo, Università Magna Graecia, 
Catanzaro; Vaccher Emanuela, Centro di Riferimento On-
cologico di Aviano; Viscoli Claudio, Università degli Studi di 
Genova; Visintini Raffaele, Ospedale San Raffaele, Milano; 
Vullo Vincenzo, Università degli Studi di Roma La Sapienza, 
Roma; Zaccarelli Mauro, Istituto Nazionale di Malattie In-
fettive L. Spallanzani, Roma; Zuccotti Gian Vincenzo, Uni-
versità degli Studi di Milano.
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